<< Back to News

Business Wire Press Release - Pfizer and BioNTech Dose First Participants in the U.S. as Part of Global COVID-19 mRNA Vaccine Development Program.

Pfizer Announcement-It is with great optimism to share yesterday’s announcement that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19 infection. The trial is part of a global development program, and the dosing of the first cohort in Germany was completed last week.

Here is the press release link with more information. https://www.businesswire.com/news/home/20200505005474/en/Pfizer-BioNTech-Dose-Participants-U.S.-Part-Global